28314412 25926623 34992038 34184879 28289968 25834052 35168510 33640967 25897865 26396237 26403521 27939437 27316994 31517532 32612495 32903744 30048714 29023112 34439767 26965688 26341487 - Search Results

Year	Number of Results
2015	6
2016	4
2017	5
2018	1
2019	1
2020	2
2021	4
2022	2
2023	0

1

Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

Christensen KV, Smith GP, Williamson DS. Christensen KV, et al. Prog Med Chem. 2017;56:37-80. doi: 10.1016/bs.pmch.2016.11.002. Epub 2017 Jan 4. Prog Med Chem. 2017. PMID: 28314412 Review.

2

The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Moehle MS, Daher JP, Hull TD, Boddu R, Abdelmotilib HA, Mobley J, Kannarkat GT, Tansey MG, West AB. Moehle MS, et al. Hum Mol Genet. 2015 Aug 1;24(15):4250-67. doi: 10.1093/hmg/ddv157. Epub 2015 Apr 29. Hum Mol Genet. 2015. PMID: 25926623 Free PMC article.

3

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.

Leśniak RK, Nichols RJ, Schonemann M, Zhao J, Gajera CR, Fitch WL, Lam G, Nguyen KC, Smith M, Montine TJ. Leśniak RK, et al. Eur J Med Chem. 2022 Feb 5;229:114080. doi: 10.1016/j.ejmech.2021.114080. Epub 2021 Dec 28. Eur J Med Chem. 2022. PMID: 34992038 Free article.

4

Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate.

Williamson DS, Smith GP, Mikkelsen GK, Jensen T, Acheson-Dossang P, Badolo L, Bedford ST, Chell V, Chen IJ, Dokurno P, Hentzer M, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Wang Y, Christensen KV. Williamson DS, et al. J Med Chem. 2021 Jul 22;64(14):10312-10332. doi: 10.1021/acs.jmedchem.1c00720. Epub 2021 Jun 29. J Med Chem. 2021. PMID: 34184879 Free article.

5

Synthesis and In Vitro and In Vivo Evaluation of [³H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.

Malik N, Gifford AN, Sandell J, Tuchman D, Ding YS. Malik N, et al. Mol Imaging Biol. 2017 Dec;19(6):837-845. doi: 10.1007/s11307-017-1070-1. Mol Imaging Biol. 2017. PMID: 28289968 Free PMC article.

6

Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.

Puccini JM, Marker DF, Fitzgerald T, Barbieri J, Kim CS, Miller-Rhodes P, Lu SM, Dewhurst S, Gelbard HA. Puccini JM, et al. J Neurosci. 2015 Apr 1;35(13):5271-83. doi: 10.1523/JNEUROSCI.0650-14.2015. J Neurosci. 2015. PMID: 25834052 Free PMC article.

7

Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.

Patel A, Patel S, Mehta M, Patel Y, Langaliya D, Bhalodiya S, Bambharoliya T. Patel A, et al. Med Chem. 2022;18(7):757-771. doi: 10.2174/1573406418666220215122136. Med Chem. 2022. PMID: 35168510 Review.

8

Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.

Bryant N, Malpeli N, Ziaee J, Blauwendraat C, Liu Z; AMP PD Consortium; West AB. Bryant N, et al. Hum Mol Genet. 2021 Apr 30;30(6):454-466. doi: 10.1093/hmg/ddab058. Hum Mol Genet. 2021. PMID: 33640967 Free PMC article.

9

Structural Characterization of LRRK2 Inhibitors.

Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A. Gilsbach BK, et al. J Med Chem. 2015 May 14;58(9):3751-6. doi: 10.1021/jm5018779. Epub 2015 May 1. J Med Chem. 2015. PMID: 25897865

10

LRRK2 autophosphorylation enhances its GTPase activity.

Liu Z, Mobley JA, DeLucas LJ, Kahn RA, West AB. Liu Z, et al. FASEB J. 2016 Jan;30(1):336-47. doi: 10.1096/fj.15-277095. Epub 2015 Sep 22. FASEB J. 2016. PMID: 26396237 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results